
|Articles|July 1, 2004
Phase III study eyes intravitreal therapy for exudative AMD
Anti-VEGF monoclonal antibody fragment improves vision, reduce fluorescein angiographic leakage
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD
3
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
4
Retina Society 2026: How blood biomarkers may predict GA speed
5










